Literature DB >> 17151941

Increasing syringe access and HIV prevention in California: findings from a survey of local health jurisdiction key personnel.

Thomas J Stopka1, Richard S Garfein, Alessandra Ross, Steven R Truax.   

Abstract

This article presents results from the first survey of California local health jurisdictions (LHJs) subsequent to passage of legislation that allows for over-the-counter pharmacy sales of syringes. In 2004 Governor Arnold Schwarzenegger signed Senate Bill 1159 (SB1159) into law to "prevent the spread of HIV, hepatitis and other blood-borne disease among drug users, their sexual partners and their children." This legislation permits counties and cities to authorize a local disease prevention demonstration project (DPDP). Once authorized, a DPDP permits individuals to legally purchase and possess up to ten syringes from registered pharmacies without a doctor's prescription. From June to August 2005, we surveyed health departments in all 61 LHJs to assess implementation status of SB1159. Fifty-seven (93%) LHJs responded. Nine (16%) had approved a DPDP by August 2005, 17 (30%) were in the process of obtaining authorization, and 18 (32%) anticipated that SB1159 would never be authorized in their LHJ. Among LHJs that do not plan to approve a DPDP (n = 18), the reasons included: strong community opposition (41%), competing priorities (35%), law enforcement opposition (29%), and little or no interest among pharmacies (29%). In LHJs that have authorized a DPDP, 31.4% of pharmacies registered to legally sell nonprescription syringes. Preliminary results indicate that local coalitions, comprised of public health, waste management and pharmacy officials, have been instrumental in facilitating DPDP authorization. Further research is needed to identify facilitators and barriers to adopting SB1159, to identify areas for improving technical assistance to implementers, and to assess the public health impact of the legislation.

Entities:  

Mesh:

Year:  2007        PMID: 17151941      PMCID: PMC2078247          DOI: 10.1007/s11524-006-9122-x

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  20 in total

1.  Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence.

Authors:  S R Friedman; T Perlis; D C Des Jarlais
Journal:  Am J Public Health       Date:  2001-05       Impact factor: 9.308

2.  The legality of selling or giving syringes to injection drug users.

Authors:  Scott Burris; Jon S Vernick; Alyssa Ditzler; Steffanie Strathdee
Journal:  J Am Pharm Assoc (Wash)       Date:  2002 Nov-Dec

Review 3.  Preventing blood-borne infections through pharmacy syringe sales and safe community syringe disposal.

Authors:  T Stephen Jones; Phillip O Coffin
Journal:  J Am Pharm Assoc (Wash)       Date:  2002 Nov-Dec

4.  Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York.

Authors:  Crystal M Fuller; Jennifer Ahern; Liza Vadnai; Phillip O Coffin; Sandro Galea; Stephanie H Factor; David Vlahov
Journal:  J Am Pharm Assoc (Wash)       Date:  2002 Nov-Dec

5.  Epidemiology of hepatitis C in the United States.

Authors:  I Williams
Journal:  Am J Med       Date:  1999-12-27       Impact factor: 4.965

Review 6.  Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence.

Authors:  Alex Wodak; Annie Cooney
Journal:  Subst Use Misuse       Date:  2006       Impact factor: 2.164

7.  Impact of increased legal access to needles and syringes on community pharmacies' needle and syringe sales--Connecticut, 1992-1993.

Authors:  L A Valleroy; B Weinstein; T S Jones; S L Groseclose; R T Rolfs; W J Kassler
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-09-01

8.  Injection drug users report good access to pharmacy sale of syringes.

Authors:  Wendy Reich; Wilson M Compton; Joeseph C Horton; Linda B Cottler; Renee M Cunningham-Williams; Robert Booth; Merrill Singer; Carl Leukefeld; Joseph Fink; Tom J Stopka; Karen Fortuin Corsi; Michelle Staton Tindall
Journal:  J Am Pharm Assoc (Wash)       Date:  2002 Nov-Dec

9.  Pharmacist ambivalence about sale of syringes to injection drug users.

Authors:  Wendy Reich; Wilson M Compton; Joe C Horton; Linda B Cottler; Renee M Cunningham-Williams; Robert Booth; Merrill Singer; Carl Leukefeld; Joseph Fink; Tom Stopka; Karen Fortuin Corsi; Michelle Staton Tindall
Journal:  J Am Pharm Assoc (Wash)       Date:  2002 Nov-Dec

10.  A multistate trial of pharmacy syringe purchase.

Authors:  Wilson M Compton; Joe C Horton; Linda B Cottler; Robert Booth; Carl G Leukefeld; Merrill Singer; Renee Cunningham-Williams; Wendy Reich; Karen Fortuin Corsi; Michele Staton; Joseph L Fink; Thomas J Stopka; Edward L Spitznagel
Journal:  J Urban Health       Date:  2004-12       Impact factor: 3.671

View more
  10 in total

1.  Injection drug users' perspectives on placing HIV prevention and other clinical services in pharmacy settings.

Authors:  Alexandra Lutnick; Patricia Case; Alex H Kral
Journal:  J Urban Health       Date:  2012-04       Impact factor: 3.671

2.  Pharmacy syringe purchase test of nonprescription syringe sales in San Francisco and Los Angeles in 2010.

Authors:  Alexandra Lutnick; Erin Cooper; Chaka Dodson; Ricky Bluthenthal; Alex H Kral
Journal:  J Urban Health       Date:  2013-04       Impact factor: 3.671

3.  Non-prescription syringe sales in California: a qualitative examination of practices among 12 local health jurisdictions.

Authors:  Valerie J Rose; Glenn Backes; Alexis Martinez; Willi McFarland
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

4.  Demographic, risk, and spatial factors associated with over-the-counter syringe purchase among injection drug users.

Authors:  Thomas J Stopka; Alexandra Lutnick; Lynn D Wenger; Kathryn Deriemer; Estella M Geraghty; Alex H Kral
Journal:  Am J Epidemiol       Date:  2012-05-04       Impact factor: 4.897

5.  Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.

Authors:  Thomas J Stopka; Ashley Donahue; Marguerite Hutcheson; Traci C Green
Journal:  J Am Pharm Assoc (2003)       Date:  2017-02-08

6.  Factors associated with presence of pharmacies and pharmacies that sell syringes over-the-counter in Los Angeles County.

Authors:  Thomas J Stopka; Estella M Geraghty; Rahman Azari; Ellen B Gold; Kathryn Deriemer
Journal:  J Urban Health       Date:  2013-12       Impact factor: 3.671

7.  Three years after legalization of nonprescription pharmacy syringe sales in California: where are we now?

Authors:  Richard S Garfein; Thomas J Stopka; Patricia B Pavlinac; Alessandra Ross; B Karen Haye; Elise D Riley; Ricky N Bluthenthal
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

8.  Access to sterile syringes through San Francisco pharmacies and the association with HIV risk behavior among injection drug users.

Authors:  Elise D Riley; Alex H Kral; Thomas J Stopka; Richard S Garfein; Paul Reuckhaus; Ricky N Bluthenthal
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

9.  Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco counties, 2007.

Authors:  Erin N Cooper; Chaka Dodson; Thomas J Stopka; Elise D Riley; Richard S Garfein; Ricky N Bluthenthal
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

10.  Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California.

Authors:  Paulo Telles Dias; Judith A Hahn; Eric Delwart; Brian Edlin; Jeff Martin; Paula Lum; Jennifer Evans; Alex Kral; Steve Deeks; Michael P Busch; Kimberly Page
Journal:  BMC Infect Dis       Date:  2011-08-02       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.